The strong share count increases by Schwab and UBS suggest underlying demand, but the drop in position value indicates LYEL's stock price declined during the quarter. Traders should assess whether the passive buying reflects index inclusion or rebalancing rather than fundamental optimism. Monitor next earnings report for catalysts that could resolve institutional divergence.
Executive Summary
In Q4 2024, three mega-passive institutions — Wells Fargo, Schwab, and UBS — increased their positions in Lyell Immunopharma (LYEL), with UBS doubling its stake. This buying activity was partially offset by a significant trim from Morgan Stanley, which reduced its holdings by nearly 30%. The cluster shows divergent views among passive managers, but the largest net increase came from UBS, suggesting growing institutional interest despite overall negative net value change due to share price decline.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$1.2M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| UBS | DOUBLED | +695% | $553.0K | $403.0K |
| Schwab | ADD | +43.4% | $1.1M | -$530.1K |
| Wells Fargo | ADD | +27.8% | $60.0K | -$41.4K |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | TRIM | -29.7% | $2.4M | -$1.6M |
Key Facts
- UBS doubled its position in LYEL, increasing shares from 108.7K to 864.3K (+755.6K shares), with value rising by $403K.
- Schwab added 498.4K shares (+43.4%), though value dropped from $1.6M to $1.1M due to falling stock price.
- Wells Fargo increased shares by 20.5K (+27.8%), but position value fell $41,449.
- Morgan Stanley trimmed 513,621 shares (-29.7%), reducing position value by $1.6M.
- All institutions involved are classified as mega-passive, indicating index-driven or rules-based strategies rather than active conviction.
Financial Impact
Institutions accumulated $403K in net new value (after accounting for market moves), while one major holder reduced exposure by $1.6M. Total position value among tracked funds decreased due to share price decline despite share count growth.
Risk Factors
- All activity comes from passive managers — moves may reflect index rebalancing, not fundamental views.
- Net value of positions declined across buyers despite share accumulation, signaling possible downward price pressure on LYEL stock.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-LYEL-2024-Q4 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | Insider Cluster | $15.49 $10.53 | ▼ −32.02% | ▼ −33.00% | — |
Jul 22, 2026 10w ago | EFFECT | $12.84 $15.76 | ▲ +22.74% | ▲ +19.84% | — |
Jun 15, 2026 15w ago | Insider Cluster | $12.44 $13.40 | ▲ +7.72% | ▲ +7.52% | — |
Jun 12, 2026 16w ago | Press Release | $13.50 $15.01 | ▲ +11.19% | ▲ +9.41% | — |
Jun 8, 2026 16w ago | Press Release | $12.31 $14.04 | ▲ +14.05% | ▲ +12.42% | — |
Jun 4, 2026 17w ago | Press Release | $11.97 $14.04 | ▲ +17.29% | ▲ +15.43% | — |
Apr 24, 2026 23w ago | DEFA14A | $22.62 $16.37 | ▼ −27.63% | ▼ −32.59% | — |
Apr 15, 2026 24w ago | EFFECT | $23.84 $19.25 | ▼ −19.25% | ▼ −25.30% | — |
Apr 3, 2026 26w ago | S-3 | $21.69 $20.72 | ▼ −4.47% | ▼ −13.45% | — |
Mar 12, 2026 29w ago | Press Release | $21.25 $24.80 | ▲ +16.71% | ▲ +13.12% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access